MX2023008785A - Mutaciones en regiones constantes de anticuerpos caninos. - Google Patents

Mutaciones en regiones constantes de anticuerpos caninos.

Info

Publication number
MX2023008785A
MX2023008785A MX2023008785A MX2023008785A MX2023008785A MX 2023008785 A MX2023008785 A MX 2023008785A MX 2023008785 A MX2023008785 A MX 2023008785A MX 2023008785 A MX2023008785 A MX 2023008785A MX 2023008785 A MX2023008785 A MX 2023008785A
Authority
MX
Mexico
Prior art keywords
mutations
canine antibody
constant regions
antibody constant
canine
Prior art date
Application number
MX2023008785A
Other languages
English (en)
Spanish (es)
Inventor
Sandra Ann Marie Lightle
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2023008785A publication Critical patent/MX2023008785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023008785A 2021-01-28 2022-01-27 Mutaciones en regiones constantes de anticuerpos caninos. MX2023008785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163142774P 2021-01-28 2021-01-28
PCT/US2022/014146 WO2022165067A2 (en) 2021-01-28 2022-01-27 Mutations in canine antibody constant regions

Publications (1)

Publication Number Publication Date
MX2023008785A true MX2023008785A (es) 2023-12-14

Family

ID=80786846

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008785A MX2023008785A (es) 2021-01-28 2022-01-27 Mutaciones en regiones constantes de anticuerpos caninos.

Country Status (15)

Country Link
US (1) US20240059777A1 (https=)
EP (2) EP4284825A2 (https=)
JP (1) JP2024505072A (https=)
KR (1) KR20230136604A (https=)
CN (1) CN116802205A (https=)
AU (1) AU2022214843A1 (https=)
CA (1) CA3207285A1 (https=)
CL (2) CL2023002202A1 (https=)
CO (1) CO2023009994A2 (https=)
EC (1) ECSP23057156A (https=)
IL (1) IL304522A (https=)
MX (1) MX2023008785A (https=)
PE (1) PE20231919A1 (https=)
TW (1) TW202246318A (https=)
WO (1) WO2022165067A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
WO2022165067A2 (en) 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions
CN119968390A (zh) * 2022-09-02 2025-05-09 硕腾服务有限责任公司 猪抗体突变体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2022165067A2 (en) 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions

Also Published As

Publication number Publication date
WO2022165067A2 (en) 2022-08-04
EP4284825A2 (en) 2023-12-06
EP4512416A3 (en) 2025-06-18
JP2024505072A (ja) 2024-02-02
CL2024001562A1 (es) 2024-08-23
CN116802205A (zh) 2023-09-22
IL304522A (en) 2023-09-01
CO2023009994A2 (es) 2023-08-09
WO2022165067A3 (en) 2022-09-22
ECSP23057156A (es) 2023-08-31
EP4512416A2 (en) 2025-02-26
US20240059777A1 (en) 2024-02-22
CL2023002202A1 (es) 2024-01-12
AU2022214843A1 (en) 2023-07-20
CA3207285A1 (en) 2022-08-04
TW202246318A (zh) 2022-12-01
AU2022214843A9 (en) 2024-05-16
KR20230136604A (ko) 2023-09-26
PE20231919A1 (es) 2023-11-28

Similar Documents

Publication Publication Date Title
PH12022552742A1 (en) Canine antibody variants
MX2023008785A (es) Mutaciones en regiones constantes de anticuerpos caninos.
PH12022552743A1 (en) Feline antibody variants
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
WO2019224716A8 (en) Antibodies specific for gucy2c and uses thereof
MX2023005896A (es) Variantes de anticuerpos bovinos.
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
ZA202213434B (en) Anti-lilrb1 antibody and uses thereof
CL2024001519A1 (es) Mutaciones en regiones constantes de anticuerpos felinos.
WO2022067233A3 (en) Canine antibody variants
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
MX2025009475A (es) Anticuerpo anti-cntn4 y usos de este
GEAP202415617A (en) Antibody variants
MX2023003694A (es) Variantes de anticuerpos felinos.
MX2025001433A (es) Mutantes de anticuerpos bovinos
MX2025002522A (es) Mutantes de anticuerpos porcinos
MX2024013189A (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos